Protherics PLC, the biopharmaceutical company focused on critical care and oncology (the “Company”), received notification on 18 April 2006 from Legal & General Investment Management Limited that Legal & General Group PLC and/or its subsidiaries (“Legal & General”) has a notifiable interest in 7,964,796 ordinary shares, representing 3.06% of the issued share capital of the Company.
